Авторы

  • Закирова Г.А.

Ключевые слова:

сахарный диабет 2 типа, хроническая сердечная недостаточность, фенотип, сохранённая фракция выброса, диабетическая кардиомиопатия, диастолическая дисфункция, ингибиторы SGLT2.

Библиографические ссылки

1. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29-34. DOI:10. 1016/0002-9149(74)90089-7.

2. Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America. Circulation. 2019;140(7):e294-e324. DOI:10.1161/CIR.0000000000000691.

3. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. DOI:10.1093/eurheartj/ehab368.

4. Seferović PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36( 27):1718-1727. DOI:10.1093/eurheartj/ehv134.

5. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39): 4043-4140. DOI:10.1093/eurheartj/ehad192.

6. Hoek AG, Dal Canto E, Wenker E, Bindraban N, Handoko ML, Elders PJM, et al. Epidemiology of heart failure in diabetes: a disease in disguise. Diabetologia. 2024;67(4):574-601. DOI:10.1007/s0 0125-023-06068-2.

7. Gil-Millan P, Gimeno-Orna JA, Rodriguez-Padial L, Muniz J, Barrios V, Anguita M, et al. HFpEF as the predominant and underrecognized heart failure phenotype in type 2 diabetes: evidence from the DIABET-IC study. Cardiovasc Diabetol. 2025;24:419. DOI:10.1186/s12933-025-02995-z.

8. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-271. DOI:10.1016/j.jacc.2013.02.092.

9. Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020; 17(9):585-607. DOI:10.1038/s41569-020-0339-2.

10. Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S, et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-Preserve trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation. 2017;135(8):724-735. DOI:10.1161/CIRCULATIONAHA.116.024593.

11. Lindman BR, Dávila-Román VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, et al. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol. 2014;64(6):541-549. DOI: 10.1016/j.jacc.2014. 05.030.

12. Lejeune S, Roy C, Slimani A, Pasquet A, Vancraeynest D, Vanoverschelde JL, et al. Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort. Cardiovasc Diabetol. 2021; 20:48. DOI:10.1186 /s12933-021-01242-5.

13. McHugh K, DeVore AD, Wu J, Matsouaka RA, Fonarow GC, Heidenreich PA, et al. Heart failure with preserved ejection fraction and diabetes: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73 (5):602-611. DOI: 10.1016/j.jacc.2018.11.033.

14. Packer M. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. J Am Coll Cardiol. 2018;71 (20):2360-2372. DOI: 10.1016/j.jacc.2018.03.509.

15. Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail. 2016;9(1): e002 560. DOI:10.1161/CIRCHEARTFAILURE.115.00256

16. Dauriz M, Mantovani A, Bonapace S, Verlato G, Zoppini G, Bonora E, et al. Prognostic impact of diabetes on long-term survival outcomes in patients with heart failure: a meta-analysis. Diabetes Care. 2017;40(11):1597-1605. DOI:10.2337/dc17-0697.

17. Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015;131(3):269-279. DOI:10.1161/circulationaha.114.010637.

18. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757-767. DOI:10.10 16/S0140-6736(22)01429-5.

19. Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394-1407. DOI:10.1056/NEJMoa2313917.

20. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427-437. DOI:10.1056/NEJ Moa2410027.

21. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. DOI:10.1056/NEJMoa1911303.

22. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. DOI:10.1056/NEJ Moa2022190.

23. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. DOI:10.1056/NEJMoa21 07038.

24. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12): 1089-1098. DOI:10.1056/NEJMoa2206286.